R&D
Virtual R&D

ST Pharm Virtual R&D

Innovative virtual R&D strategy

It enables us to implement A&D (Acquisition & Development) and C&D (Connection & Development) so that we can achieve desirable results with low cost and high efficiency.
Collaboration
Incubation
New Drug

C&D

  • DGMIF
  • Asan Medical Center
  • KRICT
  • KRIBB
  • K Bio Health
  • KAERI

A&D

  • KHU
  • Konkuk University
  • Seoul National University
  • Sogang University
  • Institute Pasteur
  • Colorado University
  • Emory University

CxOs

ST Pharm’s New drug Pipeline

ST PHARM has world-class two pipelines
('First in class')
  • 1Anti HIV /AIDS
    First in class
  • 2Anti – cancer (colorectal)
    First in class
Pipeline
(Indication)
Drug Class
Right /
Collaborator
Stage
Discovery
Pre-Clinical
Phase 1
Phase 2
Phase 3
STP0404
(Anti HIV /AIDS)
Small molecule
Emory Univ.
Colorado State Univ.
  • Tankyrase Inhibitor
STP1002
(Anti–cancer, colorectal)
Small molecule
Asan Hospital (KOREA)
  • HIV Integrase Inhibitor
STP2104
(Vaccine, COVID-19)
mRNA
Fully-owned
STP2130
(Vaccine, COVID-19)
mRNA
Fully-owned
NASH
Small molecule
Korea Research Institute of Chemical technology
Oral Heparin
Small molecule
SNU (KOREA) B&L Deli Pharm
  • Deep vein thrombosis
  • Cancer-associated thrombosis
Influenza Virus
Small molecule
OncoCross
Anti – virus
Small molecule
KRICT & Institute Pasteur Korea
Others
Small molecule
Undisclosed